- Home
- TILE vs BCYC Comparison
TILE vs BCYC Comparison
Compare TILE & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TILE
- BCYC
- Stock Information
- Founded
- TILE 1973
- BCYC 2009
- Country
- TILE United States
- BCYC United Kingdom
- Employees
- TILE N/A
- BCYC N/A
- Industry
- TILE Home Furnishings
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- TILE Consumer Discretionary
- BCYC Health Care
- Exchange
- TILE Nasdaq
- BCYC Nasdaq
- Market Cap
- TILE 1.5B
- BCYC 1.7B
- IPO Year
- TILE N/A
- BCYC 2019
- Fundamental
- Price
- TILE $24.57
- BCYC $14.68
- Analyst Decision
- TILE Buy
- BCYC Buy
- Analyst Count
- TILE 2
- BCYC 9
- Target Price
- TILE $22.00
- BCYC $35.25
- AVG Volume (30 Days)
- TILE 600.8K
- BCYC 894.6K
- Earning Date
- TILE 11-01-2024
- BCYC 02-18-2025
- Dividend Yield
- TILE 0.16%
- BCYC N/A
- EPS Growth
- TILE 11277.07
- BCYC N/A
- EPS
- TILE 1.44
- BCYC N/A
- Revenue
- TILE $1,305,766,000.00
- BCYC $36,898,000.00
- Revenue This Year
- TILE $6.86
- BCYC $40.52
- Revenue Next Year
- TILE $3.56
- BCYC N/A
- P/E Ratio
- TILE $17.05
- BCYC N/A
- Revenue Growth
- TILE 2.66
- BCYC 48.60
- 52 Week Low
- TILE $11.48
- BCYC $12.17
- 52 Week High
- TILE $27.34
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- TILE 45.14
- BCYC 28.02
- Support Level
- TILE $24.15
- BCYC $12.17
- Resistance Level
- TILE $26.43
- BCYC $17.04
- Average True Range (ATR)
- TILE 0.78
- BCYC 1.44
- MACD
- TILE -0.41
- BCYC -0.41
- Stochastic Oscillator
- TILE 19.47
- BCYC 26.90
About TILE Interface Inc.
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments - AMS and EAAA.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.